In contrast, STAG2 or STAG3 mutation in melanoma conferred resistance to BRAF inhibition owing to reactivation of MEK-MAPK (ERK) signaling, which suggests that in a melanoma context, STAG2 mutation status could inform therapeutics [189]. This evidence concerns the gene STAG3 and melanoma.